IMV Inc. (IMV)

NASDAQ: IMV · IEX Real-Time Price · USD
0.530
+0.020 (3.92%)
At close: Mar 21, 2023, 4:00 PM
0.514
-0.016 (-3.08%)
After-hours: Mar 21, 2023, 7:42 PM EDT
3.92%
Market Cap 6.50M
Revenue (ttm) 240,146
Net Income (ttm) -27.73M
Shares Out 12.27M
EPS (ttm) -3.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 50,240
Open 0.510
Previous Close 0.510
Day's Range 0.510 - 0.533
52-Week Range 0.490 - 15.300
Beta 1.40
Analysts Buy
Price Target 18.63 (+3,415.09%)
Earnings Date Mar 16, 2023

About IMV

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 97
Stock Exchange NASDAQ
Ticker Symbol IMV
Full Company Profile

Financial Performance

In 2022, IMV Inc.'s revenue was 329,000, an increase of 75.00% compared to the previous year's 188,000. Losses were -37.99 million, 3.83% more than in 2021.

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for IMV stock is "Buy." The 12-month stock price forecast is $18.63, which is an increase of 3,415.09% from the latest price.

Price Target
$18.63
(3,415.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune...

5 days ago - Business Wire

IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, bas...

1 week ago - Business Wire

IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc.

1 month ago - Business Wire

IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-ed...

2 months ago - Business Wire

IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies b...

3 months ago - Business Wire

IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies b...

3 months ago - Business Wire

IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-ed...

3 months ago - Business Wire

IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune...

3 months ago - Business Wire

IMV Shareholders Approve Reverse Stock Split at 88%

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educatin...

3 months ago - Business Wire

IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies ...

4 months ago - Business Wire

IMV Inc. Announces Third Quarter 2022 Financial and Operational Results

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies ba...

4 months ago - Business Wire

IMV Provides an Update on The VITALIZE Trial

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-ed...

6 months ago - Business Wire

IMV Inc. Announces Strategic Reorganization

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educa...

6 months ago - Business Wire

IMV Inc. to Present at Two Investor Conferences in September

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies ...

7 months ago - Business Wire

IMV Inc. Announces Second Quarter 2022 Financial and Operational Results

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing...

7 months ago - Business Wire

IMV Re-Establishes Its At-the-Market Facility Under Renewed Base Shelf Prospectus

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of im...

8 months ago - Business Wire

IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of im...

8 months ago - Business Wire

Horizon Technology Finance Provides Second Quarter 2022 Portfolio Update

-     Horizon Platform Originates Record $192 Million of New Loans in Q2, Including $137 Million of New Loans for HRZN -  -     Horizon Platform Ends Quarter with Record Committed Backlog of $267 Mill...

Other symbols: HRZN
8 months ago - PRNewsWire

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies bas...

9 months ago - Business Wire

IMV Announces Annual and Special Meeting of Shareholders Voting Results

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies bas...

9 months ago - Business Wire

IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt Facility

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® plat...

Other symbols: HRZN
9 months ago - Business Wire

IMV Inc. to Present at the H.C. Wainwright Global Investment Conference

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® plat...

11 months ago - Business Wire

IMV Inc. Announces First Quarter 2022 Financial and Operational Results

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® plat...

11 months ago - Business Wire

IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies bas...

11 months ago - Business Wire